Rachel Huckfeldt, MD, PhD, a clinical researcher and assistant professor of ophthalmology at Mass Eye and Ear, talks with host Ben Shaberman about caring for patients with inherited retinal diseases (IRD), the challenges and opportunities with clinical trials, and the educational and professional journey that led her to the IRD research field.

The emerging RNA therapy is designed to boost expression of the PRPF31 protein

Alex Cohen, PhD, a marketing professor with retinitis pigmentosa, talks with host Ben Shaberman about his career in the hospitality industry and launch of Accessible Pharmacy, a comprehensive pharmacy service for people with vision loss.

Jami Kern, PhD, chief clinical officer at Nacuity Pharmaceuticals, talks with host Ben Shaberman about NACA, the company's emerging gene-agnostic therapy for Usher syndrome and retinitis pigmentosa in a Phase 2 clinical trial in Australia. Their conversation includes a discussion about oxidative stress, which NACA is designed to mitigate, and timing for the efficacy readout from the Phase 2 study.

Kari Branham, a genetic counselor with Kellog Eye Center at the University of Michigan, talks to host Ben Shaberman about a variety of topics related to genetic testing and counseling for people with inherited retinal diseases. Their conversation includes discussion of: common misconceptions about genetic testing, variants of unknown significance, when re-testing makes sense, and when and if family members should be tested.

The company is expanding the trial to enroll younger patients with less advanced disease

Aaron Osborne, MD, chief medical officer and chief development officer at Nanoscope Therapeutics, talks about vision restoration in clinical trials of the company's optogenetic therapy for people with advanced vision loss from retinitis pigmentosa and Stargardt disease.

Known as The Lighthouse Study, the Phase 1/2 trial is expected to begin in mid-2023

During his Proctor Award Lecture, Dr. Pierce reviewed encouraging clinical trial results for Editas’ CRISPR/Cas9 treatment for people with LCA10

News | Budd Tucker Honored with Award for Advancements in Retinal Therapy Development by Foundation Fighting Blindness